Johnson & Johnson’s RYBREVANT approved by FDA as second-line option for EGFR-mutated NSCL
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s RYBREVANT (amivantamab-vmjw) in combination with chemotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that features epidermal growth factor receptor (EGFR) exon 19 deletions or L858R substitution mutations. This approval targets patients whose disease has […]